Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Genitourinary Cancer Specialty Channel

Genitourinary Cancer
Specialty Channel
Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
Quiz
03/29/2022
In the largest randomized study conducted to date in this population, ________ is the first immunotherapy to demonstrate a statistically significant and clinically meaningful survival benefit in R/M cervical carcinoma following progression...
In the largest randomized study conducted to date in this population, ________ is the first immunotherapy to demonstrate a statistically significant and clinically meaningful survival benefit in R/M cervical carcinoma following progression...
In the largest randomized study...
03/29/2022
Oncology
News
02/23/2022

John Otrompke

John Otrompke
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be...
02/23/2022
Oncology
Test Your Knowledge
11/29/2021
According to data presented at the ASCO Annual Meeting, the combination of niraparib and dostarlimab displays a clinical benefit rate of _______ at 16w in patients with recurrent endometrial carcinoma.
According to data presented at the ASCO Annual Meeting, the combination of niraparib and dostarlimab displays a clinical benefit rate of _______ at 16w in patients with recurrent endometrial carcinoma.
According to data presented at...
11/29/2021
Oncology
Test Your Knowledge
11/24/2021
The _____ multicentric trial evaluated dostarlimab in combination with niraparib versus niraparib alone, compared to chemotherapy, in the treatment of endometrial/ovarian carcinosarcoma following at least one line of platinum based...
The _____ multicentric trial evaluated dostarlimab in combination with niraparib versus niraparib alone, compared to chemotherapy, in the treatment of endometrial/ovarian carcinosarcoma following at least one line of platinum based...
The _____ multicentric trial...
11/24/2021
Oncology
Test Your Knowledge
11/23/2021
True or False: The enrichment of germline BRCA1/2 PVs in type II cancers is consistent with prior reports that non-endometrioid tumors are frequently deficient in homologous recombination.
True or False: The enrichment of germline BRCA1/2 PVs in type II cancers is consistent with prior reports that non-endometrioid tumors are frequently deficient in homologous recombination.
True or False: The enrichment of...
11/23/2021
Oncology
News
04/13/2021
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated...
04/13/2021
Oncology
Test Your Knowledge
02/19/2021
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does...
02/19/2021
Oncology
News
02/19/2021
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based...
02/19/2021
Oncology
Test Your Knowledge
11/03/2020
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by...
11/03/2020
Oncology
Test Your Knowledge
07/31/2020
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or false: Ipilimumab plus...
07/31/2020
Oncology

Advertisement

News

Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
News
02/23/2022

John Otrompke

John Otrompke
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be...
02/23/2022
Oncology
News
04/13/2021
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated...
04/13/2021
Oncology
News
02/19/2021
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based...
02/19/2021
Oncology
News
07/29/2020
Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic RCC previously given immune checkpoint inhibitors.
Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic RCC previously given immune checkpoint inhibitors.
Ipilimumab plus nivolumab...
07/29/2020
Oncology
News
07/27/2020
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
Pembrolizumab was active in...
07/27/2020
Oncology
News
07/01/2020
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing chemotherapy.
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing chemotherapy.
The FDA approved avelumab for...
07/01/2020
Oncology
News
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
05/01/2020
Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.
Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.
Switch maintenance pembrolizumab...
05/01/2020
Oncology
News
05/01/2020
Findings from a large retrospective study suggest that teratoma is not a prognostic factor in patients with metastatic testicular germ cell tumors.
Findings from a large retrospective study suggest that teratoma is not a prognostic factor in patients with metastatic testicular germ cell tumors.
Findings from a large...
05/01/2020
Oncology

Interactive Features

Quiz
03/29/2022
In the largest randomized study conducted to date in this population, ________ is the first immunotherapy to demonstrate a statistically significant and clinically meaningful survival benefit in R/M cervical carcinoma following progression...
In the largest randomized study conducted to date in this population, ________ is the first immunotherapy to demonstrate a statistically significant and clinically meaningful survival benefit in R/M cervical carcinoma following progression...
In the largest randomized study...
03/29/2022
Oncology
Test Your Knowledge
11/29/2021
According to data presented at the ASCO Annual Meeting, the combination of niraparib and dostarlimab displays a clinical benefit rate of _______ at 16w in patients with recurrent endometrial carcinoma.
According to data presented at the ASCO Annual Meeting, the combination of niraparib and dostarlimab displays a clinical benefit rate of _______ at 16w in patients with recurrent endometrial carcinoma.
According to data presented at...
11/29/2021
Oncology
Test Your Knowledge
11/24/2021
The _____ multicentric trial evaluated dostarlimab in combination with niraparib versus niraparib alone, compared to chemotherapy, in the treatment of endometrial/ovarian carcinosarcoma following at least one line of platinum based...
The _____ multicentric trial evaluated dostarlimab in combination with niraparib versus niraparib alone, compared to chemotherapy, in the treatment of endometrial/ovarian carcinosarcoma following at least one line of platinum based...
The _____ multicentric trial...
11/24/2021
Oncology
Test Your Knowledge
11/23/2021
True or False: The enrichment of germline BRCA1/2 PVs in type II cancers is consistent with prior reports that non-endometrioid tumors are frequently deficient in homologous recombination.
True or False: The enrichment of germline BRCA1/2 PVs in type II cancers is consistent with prior reports that non-endometrioid tumors are frequently deficient in homologous recombination.
True or False: The enrichment of...
11/23/2021
Oncology
Test Your Knowledge
02/19/2021
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does...
02/19/2021
Oncology
Test Your Knowledge
11/03/2020
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by...
11/03/2020
Oncology
Test Your Knowledge
07/31/2020
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or false: Ipilimumab plus...
07/31/2020
Oncology
Test Your Knowledge
06/22/2020
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.
True or False: Enfortumab...
06/22/2020
Oncology
Test Your Knowledge
05/05/2020
True or false: Teratoma is a prognostic factor in patients with metastatic testicular germ cell tumors.
True or false: Teratoma is a prognostic factor in patients with metastatic testicular germ cell tumors.
True or false: Teratoma is a...
05/05/2020
Oncology
Test Your Knowledge
10/01/2019
True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.
True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.
True or False: Combining...
10/01/2019
Oncology

Advertisement

Advertisement

Advertisement

Advertisement